MBX Biosciences (MBX) Long-Term Deferred Tax (2025 - 2026)

MBX Biosciences (MBX) reported Long-Term Deferred Tax of $332000.0 for Q1 2026, down 2.64% sequentially from $341000.0 in Q4 2025.

MBX Biosciences (MBX) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends

MBX Biosciences (MBX) has 2 years of Long-Term Deferred Tax data on file, last reported at $332000.0 in Q1 2026.

For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $332000.0; the trailing twelve-month figure through Mar 2026 stood at $332000.0 (changed N/A YoY), and the FY2025 full-year result was $341000.0, changed N/A from the prior year.
Long-Term Deferred Tax fell to $332000.0 in Q1 2026, from $341000.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $341000.0 in Q4 2025 to a low of $332000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	MBX Biosciences	2.96 Bn	2.96 Bn	-

Download Data

Date	Value
Mar 31, 2026	332,000.00
Dec 31, 2025	341,000.00